文献速递胸部肿瘤

LIBRETTO-001研究中接受或不接受既往免疫检查点抑制剂治疗的NSCLC患者对塞尔帕替尼的超敏反应

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.
PubMed 文献 · J Thorac Oncol · 2022-02-17

基于LIBRETTO-001 1/2期试验截至2019年12月16日入组患者的数据,分析RET融合阳性NSCLC患者中塞尔帕替尼相关超敏反应。329例中22例(7%)发生1-3级超敏反应,研究者归因于塞尔帕替尼,既往ICI治疗者(17例,77%)多于未接受ICI者(5例,23%)。超敏反应可通过支持治疗管理且可逆。

要点

  • 塞尔帕替尼相关超敏反应总体发生率低,为7%(22/329)。
  • 超敏反应多见于既往接受ICI治疗者(17例,77%),未接受ICI者5例(23%)。
  • 19例患者在超敏反应后经剂量调整/支持治疗重启塞尔帕替尼,其中17例仍在治疗。

核心结论

  • 塞尔帕替尼相关超敏反应发生率总体较低,且与其他激酶抑制剂类似,主要发生于既往ICI治疗患者。
  • 无论既往ICI状态如何,塞尔帕替尼超敏反应可通过支持治疗措施管理,且可逆。

研究设计与样本

  • 分析正在进行的1/2期LIBRETTO-001试验(NCT03157128)中截至2019年12月16日入组患者的数据。

主要发现

  • 329例患者中22例(7%)发生研究者归因于塞尔帕替尼的1-3级超敏反应,符合预设症状群定义。
  • 22例中既往ICI治疗者17例(77%),未接受ICI者5例(23%)。
  • 19例患者在超敏反应后经剂量调整/支持治疗重启塞尔帕替尼。
  • 17例仍在治疗中,其中14例既往接受ICI治疗,每日两次剂量为40 mg(5例)、80 mg(4例)、120 mg(4例)、160 mg(4例)。

关键数值与推荐

  • 超敏反应定义为斑丘疹,常先有发热伴关节痛/肌痛,随后出现以下至少1项:血小板减少、天冬氨酸氨基转移酶或丙氨酸氨基转移酶升高、低血压、心动过速或肌酐升高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immune checkpoint inhibitor (ICI) therapy has been found to increase the risk/severity of immune-mediated adverse events with subsequent kinase inhibitor treatment in oncogenically driven cancers. We explored the risk for hypersensitivity with selpercatinib, a first-in-class highly selective and potent, central nervous system-active RET inhibitor, in prior ICI-treated patients with RET fusion-positive NSCLC compared with their ICI-naive counterparts. METHODS: Data from patients enrolled by December 16, 2019, in the ongoing phase 1/2 LIBRETTO-001 (NCT03157128) trial were analyzed for hypersensitivity reactions reported using preferred terms of hypersensitivity/drug hypersensitivity and defined as a constellation of symptoms/findings characterized by maculopapular rash, often preceded by fever with arthralgias/myalgias, followed by greater than or equal to 1 of the following signs/symptoms: thrombocytopenia, increased aspartate aminotransferase or alanine aminotransferase, hypotension, tachycardia, or increased creatinine. RESULTS: Of 329 patients, 22 (7%) who experienced a grade 1 to 3 hypersensitivity reaction that met the defined constellation of events were attributed to selpercatinib by investigators, and more often in prior ICI-treated (n = 17, 77%) than ICI-naive (n = 5, 23%) patients. There were 19 patients with selpercatinib-related hypersensitivity who resumed selpercatinib post-hypersensitivity with dose modification/supportive care. Furthermore, 17 patients, of whom 14 received prior ICI therapy, were still on treatment at twice daily doses of 40 mg (n = 5), 80 mg (n = 4), 120 mg (n = 4), and 160 mg (n = 4). CONCLUSIONS: Rates of selpercatinib-related hypersensitivity were low overall and, as with other kinase inhibitors, occurred predominantly in prior ICI-treated patients. Hypersensitivity to selpercatinib can be managed with supportive care measures regardless of prior ICI status and is reversible.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. McCoach CE, Rolfo C, Drilon A, et al. Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001. J Thorac Oncol. 2022. PMID: 35183775. doi:10.1016/j.jtho.2022.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。